Clinical Response and Safety of Letrozole-based Therapy in Postmenopausal Sudanese Women with Estrogen Receptor-positive/HER2-Negative Breast Cancer: A Retrospective Cohort Study
Rattachement africain : Soudan, om, sa, kw. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Estrogen receptor-positive/HER2-negative breast cancer is the most common molecular subtype of breast cancer. Aromatase inhibitors such as letrozole are part of the standard endocrine treatment regimen for postmenopausal patients; however, real-world evidence on patient outcomes from resource-limited African countries remains sparse. This study assessed the efficacy and safety of letrozole-based treatment regimens in postmenopausal Sudanese patients with ER-positive/HER2-negative breast cancer. Methods: A retrospective cohort study was conducted among postmenopausal women at Khartoum Oncology Teaching Hospital, Sudan, between March 2018 and March 2020. Eligible participants were postmenopausal women with ER-positive/HER2-negative breast cancer who had received letrozole-based treatment regimens. Four groups were defined: docetaxel + letrozole, docetaxel + letrozole + radiotherapy, letrozole + radiotherapy, and mastectomy + letrozole. Data were collected from medical records, and the outcomes assessed included changes in tumour size, metastasis status, relapse, radiographic findings, and adverse effects. Descriptive and inferential non-parametric statistical analyses were performed using SPSS. Statistical significance was set at p < 0.05. Results: Forty-six participants with a median age of 58.5 years (45–73) were included. Localised disease was present in 73.9% of participants, and T3 tumours accounted for 71.7%. Docetaxel + letrozole achieved complete tumour clearance in all 11 patients and produced a statistically significant reduction in tumour size (p = 0.001). Letrozole + radiotherapy reduced tumour size by 97.1% (p < 0.001), while mastectomy + letrozole resulted in complete absence of detectable tumour after surgery (p = 0.031). The metastatic multimodal group did not demonstrate statistically significant tumour control (p = 0.063). Overall, 37.0% of participants experienced relapse, predominantly among those with metastatic or T4 disease. Arthralgia was the most common adverse effect (26.1%), followed by hot flushes (23.9%). Conclusion: Letrozole-based therapy showed favourable tumour responses in postmenopausal Sudanese women with localised hormone receptor-positive/HER2-negative breast cancer, particularly when combined with docetaxel, radiotherapy, or surgery. In contrast, metastatic disease was associated with a poor response and relapse despite combination therapy. Further studies are required to confirm these findings and evaluate survival outcomes.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Clinical Response and Safety of Letrozole-based Therapy in Postmenopausal Sudanese Women with Estrogen Receptor-positive/HER2-Negative Breast Cancer: A Retrospective Cohort Study
- Date Crossref
- 04/08/2026
- Éditeur
- Sciencedomain International
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Omdurman Islamic University Omdurman Islamic University, Soudan (code pays fourni par la source)Université ou école supérieure
-
National University of Science and Technology pays non établi dans la noticeUniversité ou école supérieure
-
University of Gezira Soudan (code pays fourni par la source)Université ou école supérieure
-
Ibn Sina National College for Medical Studies Department of Pathology and Microbiology University of Khartoum, Soudan (pays nommé en fin d’affiliation)Université ou école supérieure
-
Mashreq University Soudan (code pays fourni par la source)Université ou école supérieure
-
Ibn Sina Hospital pays non établi dans la noticeÉtablissement de santé
-
Faculty of Pharmacy Department of Pharmacology Khartoum, Soudan (pays nommé en fin d’affiliation)Université ou école supérieure
-
College of Pharmacy Department of Pharmacy Practice Wad Medani, Soudan (pays nommé en fin d’affiliation)Université ou école supérieure
-
Ibn Sina College for Medical Studies Department of Medicine and Adult Critical Care Medicine Khartoum, Soudan (pays nommé en fin d’affiliation)Université ou école supérieure
Omdurman Islamic University (Omdurman Islamic University, Soudan), National University of Science and Technology et University of Gezira (Soudan), avec 6 autres affiliations. Pays d’affiliation : Soudan.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.